Chinese medical journal
-
Chinese medical journal · Nov 2020
Randomized Controlled Trial Multicenter StudySecukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis.
Psoriasis is a chronic inflammatory skin disease, affecting about 0.6% of the Chinese population. Many patients are not well controlled by conventional treatments, thus there is need for new treatment regimens. In this study, we assessed the efficacy and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis. ⋯ Secukinumab is highly effective and well tolerated in Chinese patients with moderate to severe plaque psoriasis.